Sophiris Bio Inc. (NASDAQ:SPHS) shares saw unusually-strong trading volume on Friday . Approximately 4,610,476 shares were traded during trading, an increase of 4% from the previous session’s volume of 4,421,246 shares.The stock last traded at $5.50 and had previously closed at $5.68.

Several analysts have commented on SPHS shares. Maxim Group restated a “buy” rating and set a $4.00 target price on shares of Sophiris Bio in a report on Friday, June 10th. Echelon Wealth Partners restated a “buy” rating and set a $5.00 target price on shares of Sophiris Bio in a report on Friday, June 10th.

The firm’s market cap is $120.52 million. The stock’s 50 day moving average price is $4.20 and its 200-day moving average price is $2.17.

Sophiris Bio (NASDAQ:SPHS) last released its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.06. Analysts predict that Sophiris Bio Inc. will post ($0.69) EPS for the current fiscal year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.